The Novo Nordisk Way is a global commitment that defines who we are, where we want to go and the values that characterize our company. It is a promise we make to our patients, our employees and our stakeholders.

Producing life-saving medicines is a significant responsibility; millions of people depend on us. However, to defeat a serious chronic condition, we need to do more than supply the right medicine. This is why we work in partnerships with multiple stakeholders to raise awareness, improve prevention, promote earlier diagnosis and expand access to care.

As part of the Novo Nordisk Way, we are committed to being transparent about our interactions, especially those with research organizations, teaching hospitals, health care professionals and the overall medical community. We follow the highest ethical standards as well as all legal and regulatory requirements in our interactions with the medical community and our customers.

The Physician Payments Sunshine Act (commonly referred to as "Open Payments"), which is part of the Affordable Care Act, requires pharmaceutical manufacturers to annually report to the Centers for Medicare and Medicaid Services (CMS) certain payments and transfers of value to physicians and teaching hospitals. Open Payments promotes transparency by publishing the financial relationships between pharmaceutical manufacturers and healthcare providers (physicians and hospitals) on a publicly accessible website developed by CMS.

Additional state and local jurisdictions have laws with requirements similar to Open Payments. Novo Nordisk supports and adheres to all requirements of these laws and submits annual reports to CMS, states and other local jurisdictions as required by law.

For more information on these laws and Novo Nordisk's engagement with healthcare professionals, please contact the Ethics & Compliance Department at